These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
400 related items for PubMed ID: 20008189
1. Optimizing treatment of von Willebrand disease by using phenotypic and molecular data. Rodeghiero F, Castaman G, Tosetto A. Hematology Am Soc Hematol Educ Program; 2009; ():113-23. PubMed ID: 20008189 [Abstract] [Full Text] [Related]
2. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio. Gadisseur A, Berneman Z, Schroyens W, Michiels JJ. Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359 [Abstract] [Full Text] [Related]
3. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management. Michiels JJ, van Vliet HH. Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362 [Abstract] [Full Text] [Related]
7. Diagnosis and management of von Willebrand disease in Australia. Favaloro EJ, Bonar R, Favaloro J, Koutts J. Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198 [Abstract] [Full Text] [Related]
8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3. Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U. Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493 [Abstract] [Full Text] [Related]